Get the Stockscreener App
7.22
0.96%
-0.07
After Hours:
7.22
Sage Therapeutics Inc stock is traded at $7.22, with a volume of 464.09K.
It is down -0.96% in the last 24 hours and down -14.35% over the past month.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
See More
Previous Close:
$7.29
Open:
$7.21
24h Volume:
464.09K
Relative Volume:
0.60
Market Cap:
$441.39M
Revenue:
$91.06M
Net Income/Loss:
$-503.14M
P/E Ratio:
-0.7278
EPS:
-9.92
Net Cash Flow:
$-424.74M
1W Performance:
-0.14%
1M Performance:
-14.35%
6M Performance:
-61.47%
1Y Performance:
-64.92%
1-Day Range:
$7.01
$7.48
1-Week Range:
$6.98
$7.50
52-Week Range:
$6.98
$28.26
Sage Therapeutics Inc Stock (SAGE) Company Profile
Name
Sage Therapeutics Inc
Sector
Industry
Phone
617-299-8380
Address
215 FIRST STREET, CAMBRIDGE, MA
Sage Therapeutics Inc Stock (SAGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-23 | Initiated | Deutsche Bank | Hold |
| Aug-08-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Aug-08-23 | Downgrade | Goldman | Buy → Neutral |
| Aug-08-23 | Downgrade | Needham | Buy → Hold |
| Aug-07-23 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-07-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-07-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-07-23 | Downgrade | Stifel | Buy → Hold |
| Aug-07-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Mar-13-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jan-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-01-22 | Initiated | Loop Capital | Hold |
| Mar-31-22 | Initiated | Berenberg | Hold |
| Nov-02-21 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-07-21 | Downgrade | Jefferies | Buy → Hold |
| Sep-23-21 | Initiated | Needham | Buy |
| Jun-16-21 | Downgrade | Citigroup | Buy → Neutral |
| Apr-07-21 | Initiated | Piper Sandler | Overweight |
| Feb-26-21 | Downgrade | Mizuho | Buy → Neutral |
| Feb-25-21 | Reiterated | H.C. Wainwright | Neutral |
| Feb-02-21 | Resumed | Raymond James | Mkt Perform |
| Jan-22-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-04-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-04-20 | Upgrade | Mizuho | Neutral → Buy |
| Dec-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-06-20 | Reiterated | H.C. Wainwright | Neutral |
| Sep-11-20 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-10-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-08-20 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-08-20 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-18-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-28-20 | Reiterated | H.C. Wainwright | Neutral |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-06-19 | Reiterated | RBC Capital Mkts | Outperform |
| Dec-05-19 | Reiterated | Guggenheim | Buy |
| Dec-05-19 | Downgrade | SunTrust | Buy → Hold |
| Oct-30-19 | Initiated | H.C. Wainwright | Neutral |
| May-23-19 | Initiated | Wedbush | Outperform |
| Apr-25-19 | Initiated | Jefferies | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Oct-11-18 | Initiated | Oppenheimer | Outperform |
View All
Sage Therapeutics Inc Stock (SAGE) Latest News
SAGE THERAPEUTICS, INC. (NASDAQ: SAGE) DEADLINE ALERT: - GlobeNewswire
SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Morningstar
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel ... - Post Register
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAGE - GlobeNewswire Inc.
SAGE SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Cubist Systematic Strategies LLC Increases Stock Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE) - MarketBeat
SAGE Stockholders Have Opportunity to Lead Sage Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - AccessWire
Glancy Prongay & Murray LLP Reminds Investors of Looming - GlobeNewswire
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Sage Therapeutics, Inc. (SAGE) - GlobeNewswire Inc.
SAGE, BIIB End Collaboration for Neurology Candidate SAGE-324 - Zacks Investment Research
SAGE Therapeutics’ SAGE-324 Collaboration with Biogen Ends - Yahoo Finance
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Sage Therapeutics, Inc.(SAGE) Shareholders - PR Newswire
Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares Bought by Renaissance Technologies LLC - MarketBeat
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAGE - GlobeNewswire Inc.
Sage Therapeutics ends deal with Biogen for SAGE-324 products - Investing.com
Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate - AOL
Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate - Benzinga
Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate - Yahoo Finance
Sage Therapeutics, Biogen End Licensing Agreement for Tremor Drug - MarketWatch
Sage Therapeutics announces discontinuation of SAGE-324 pact with Biogen - TipRanks
SAGE Therapeutics Announces Discontinuation Of The Collaboration With Biogen On The Sage-324 Program - XM
Sage Therapeutics Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 Program - Business Wire
Class Action Filed Against Sage Therapeutics, Inc. (SAGE) Seeking Recovery for InvestorsContact The Gross Law Firm - Morningstar
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sage Therapeutics - GlobeNewswire
Incorrect research alert on Sage Therapeutics Inc withdrawn - XM
SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit - Morningstar
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sage Therapeutics - GlobeNewswire Inc.
Neurological diseases index falls; Sarepta and Intra-Cellular report gains - BioWorld Online
Sage Therapeutics, Inc. (SAGE) Hits 52-Week Lows After Trial Failures, According to Short Sellers - Yahoo Finance
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sage Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesSAGE - PR Newswire
Sage Therapeutics Inc (SAGE)’s results reveal risk - US Post News
SAGE SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sage Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - AccessWire
15 Worst 52-Week Low Stocks to Buy Now According to Short Sellers - Insider Monkey
SAGE LAWSUIT ALERT: The Gross Law Firm Notifies Sage - GlobeNewswire
SAGE LAWSUIT ALERT: The Gross Law Firm Notifies Sage Therapeutics, Inc. Investors of a Class Action Lawsuit - EIN News
Market Momentum Report: Sage Therapeutics Inc (SAGE)’s Negative Close at 7.23 - The Dwinnex
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sage Therapeutics - Marketscreener.com
Shareholders of Sage Therapeutics, Inc. Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your RightsSAGE - PR Newswire
A better buy-in window may exist right now for Sage Therapeutics Inc (SAGE) - SETE News
Inspire Investing LLC Purchases 13,399 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
SAGE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sage Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Sage Therapeutics (SAGE) Q2 Loss Wider Than Expected, Sales Rise - MSN
The Gross Law Firm Reminds Sage Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024SAGE - PR Newswire
Rhumbline Advisers Has $988,000 Stock Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
Rosen, Skilled Investor Counsel, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – Sage - Wahanariau
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAGE - AsiaOne
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sage Therapeutics - Marketscreener.com
(SAGE) Technical Data - Stock Traders Daily
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sage Therapeutics - AccessWire
SAGE INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Case - ForexTV.com
Sage Therapeutics Inc Stock (SAGE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):